| Code | CSB-MP009705HU(M2) |
| Abbreviation | Recombinant Human GPC3 protein (S359F), partial (Active) |
| MSDS | |
| Size | $138 |
| Order now | |
| Image | |
| Have Questions? | Leave a Message or Start an on-line Chat |
Glypican-3 serves as a critical oncofetal antigen overexpressed in hepatocellular carcinoma and other malignancies, making it a high-priority target for cancer immunotherapy development and diagnostic antibody validation. This mammalian-expressed construct spanning residues 25–559 with an S359F mutation preserves native glycosylation patterns essential for authentic receptor interactions, and demonstrates a binding affinity of 6.32 nM to anti-GPC3 antibodies in biolayer interferometry assays—a quantitative benchmark that supports its use as a coating antigen for antibody validation, integrin-binding assays, and receptor interaction studies in cancer invasion models. The low endotoxin level of less than 1.0 EU/μg combined with greater than 90% purity meets the quality thresholds commonly required for cell-based functional assays, including 3D culture systems investigating tumor microenvironment interactions and matrix remodeling experiments. Researchers studying GPC3-mediated signaling in hepatocellular carcinoma or developing therapeutic antibodies will find this construct provides a suitable basis for mechanistic studies and immunoassay standardization.
There are currently no reviews for this product.